Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Reckitt pins hopes on health product line extensions; DSM girds for further European tumult with profit improvement program; operational efficiencies grow Vitamin Shoppe margin; Omega Protein fish oil yield plummets; Vitacost.com boosts proprietary offerings; more Sales & Earnings In Brief.
You may also be interested in...
DSM Makes Waves In Omega-3 Fish Oil With Ocean Nutrition Pick-Up
The Dutch ingredients company hopes to expand Ocean Nutrition Canada into a global omega-3 fish oil supplier for foods and supplements, as well as a source for pharma ingredients. With expiring IP on the Martek algal DHA process, DSM could be seeking a hedge.
Sales & Earnings In Brief
Vitamin Shoppe shrugs off DMAA warnings; Teva grows OTCs, transitions CEO; Reckitt’s Mucinex still ahead of private label; DSM nutrition still up from Martek acquisition; more Sales & Earnings In Brief.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.